Connection

Robert Harrington to Percutaneous Coronary Intervention

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Percutaneous Coronary Intervention.
Robert Harrington
Connection Strength
10.460
Percutaneous Coronary Intervention
  1. Appropriate Use Criteria for Coronary Revascularization and the Learning Health System: A Good Start. JAMA. 2015 Nov 17; 314(19):2029-31.
    View in: PubMed
    Score: 0.452
  2. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015 Oct; 40(3):317-22.
    View in: PubMed
    Score: 0.448
  3. Selecting revascularization strategies in patients with coronary disease. N Engl J Med. 2015 Mar 26; 372(13):1261-3.
    View in: PubMed
    Score: 0.432
  4. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar; 8(3):424-433.
    View in: PubMed
    Score: 0.430
  5. Advances in understanding percutaneous coronary intervention pharmacology: ischemia, bleeding, the ISAR research group, and a commitment to progress. Coron Artery Dis. 2014 Sep; 25(6):453-5.
    View in: PubMed
    Score: 0.416
  6. Calculating risks and benefits to help guide revascularization decisions: turning all available data into useful information. J Am Coll Cardiol. 2014 Aug 05; 64(5):433-5.
    View in: PubMed
    Score: 0.414
  7. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):246-55.
    View in: PubMed
    Score: 0.388
  8. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 02; 8(8):777-785.
    View in: PubMed
    Score: 0.184
  9. Biomarker-Based Prediction of Recurrent?Ischemic Events in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2022 11 01; 80(18):1735-1747.
    View in: PubMed
    Score: 0.183
  10. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2023 Jan 01; 370:51-57.
    View in: PubMed
    Score: 0.183
  11. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. Eur Heart J Acute Cardiovasc Care. 2022 Jun 07; 11(4):336-349.
    View in: PubMed
    Score: 0.178
  12. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI. Am Heart J. 2022 07; 249:23-33.
    View in: PubMed
    Score: 0.175
  13. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circ Cardiovasc Interv. 2022 Mar; 15(3):e011069.
    View in: PubMed
    Score: 0.175
  14. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022 Feb 15; 327(7):662-675.
    View in: PubMed
    Score: 0.174
  15. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2022 01; 15(1):e010390.
    View in: PubMed
    Score: 0.172
  16. Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circ Cardiovasc Interv. 2021 12; 14(12):e011035.
    View in: PubMed
    Score: 0.172
  17. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. J Am Coll Cardiol. 2020 07 14; 76(2):162-171.
    View in: PubMed
    Score: 0.156
  18. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407.
    View in: PubMed
    Score: 0.153
  19. Association Between Current and Future Annual Hospital Percutaneous Coronary Intervention Mortality Rates. JAMA Cardiol. 2019 11 01; 4(11):1077-1083.
    View in: PubMed
    Score: 0.149
  20. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
    View in: PubMed
    Score: 0.147
  21. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 07; 12(7):e007342.
    View in: PubMed
    Score: 0.146
  22. Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circ Cardiovasc Interv. 2019 05; 12(5):e007086.
    View in: PubMed
    Score: 0.144
  23. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.
    View in: PubMed
    Score: 0.142
  24. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
    View in: PubMed
    Score: 0.140
  25. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019 Mar 01; 278:217-222.
    View in: PubMed
    Score: 0.139
  26. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. Int J Cardiol. 2018 Nov 01; 270:96-101.
    View in: PubMed
    Score: 0.135
  27. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.
    View in: PubMed
    Score: 0.134
  28. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.
    View in: PubMed
    Score: 0.134
  29. Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. Circulation. 2018 06 05; 137(23):2427-2429.
    View in: PubMed
    Score: 0.134
  30. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circ Cardiovasc Interv. 2018 04; 11(4):e005635.
    View in: PubMed
    Score: 0.133
  31. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018 02 02; 13(15):e1841-e1849.
    View in: PubMed
    Score: 0.132
  32. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.127
  33. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.
    View in: PubMed
    Score: 0.127
  34. Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.
    View in: PubMed
    Score: 0.124
  35. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 01; 10(1).
    View in: PubMed
    Score: 0.122
  36. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute?Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC Cardiovasc Interv. 2016 09 26; 9(18):1905-13.
    View in: PubMed
    Score: 0.120
  37. "Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. J Am Coll Cardiol. 2016 11 29; 68(21):2385-2387.
    View in: PubMed
    Score: 0.119
  38. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7(2):158-165.
    View in: PubMed
    Score: 0.119
  39. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. 2016 Sep 06; 134(10):723-33.
    View in: PubMed
    Score: 0.119
  40. Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression. Int J Cardiol. 2016 Nov 01; 222:1031-1039.
    View in: PubMed
    Score: 0.119
  41. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).
    View in: PubMed
    Score: 0.117
  42. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016 Apr; 102(8):617-25.
    View in: PubMed
    Score: 0.115
  43. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation. 2016 Jan 19; 133(3):248-55.
    View in: PubMed
    Score: 0.114
  44. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheter Cardiovasc Interv. 2016 Aug; 88(2):163-73.
    View in: PubMed
    Score: 0.114
  45. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
    View in: PubMed
    Score: 0.113
  46. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45.
    View in: PubMed
    Score: 0.113
  47. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016 Apr 07; 37(14):1122-30.
    View in: PubMed
    Score: 0.112
  48. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):357-67.
    View in: PubMed
    Score: 0.110
  49. Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv. 2015 Jun; 8(6):e002314.
    View in: PubMed
    Score: 0.110
  50. Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. Am Heart J. 2015 Aug; 170(2):371-9.
    View in: PubMed
    Score: 0.109
  51. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014 Aug; 7(8):857-67.
    View in: PubMed
    Score: 0.103
  52. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.
    View in: PubMed
    Score: 0.103
  53. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014 Feb 25; 63(7):619-629.
    View in: PubMed
    Score: 0.098
  54. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J. 2013 Oct; 166(4):723-8.
    View in: PubMed
    Score: 0.097
  55. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.
    View in: PubMed
    Score: 0.097
  56. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. Am Heart J. 2013 Sep; 166(3):466-73.
    View in: PubMed
    Score: 0.096
  57. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul; 6(7):671-83.
    View in: PubMed
    Score: 0.096
  58. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013 Jul 16; 62(3):242-251.
    View in: PubMed
    Score: 0.095
  59. Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014 Mar; 3(1):37-45.
    View in: PubMed
    Score: 0.095
  60. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013 Sep; 99(17):1282-7.
    View in: PubMed
    Score: 0.094
  61. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun; 165(6):918-925.e2.
    View in: PubMed
    Score: 0.093
  62. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
    View in: PubMed
    Score: 0.091
  63. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. Int J Cardiol. 2013 Sep 10; 167(6):2580-7.
    View in: PubMed
    Score: 0.090
  64. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.
    View in: PubMed
    Score: 0.037
  65. Use of Antiplatelet Therapy/DAPT for?Post-PCI Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2017 Apr 11; 69(14):1861-1870.
    View in: PubMed
    Score: 0.031
  66. The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS One. 2017; 12(1):e0169108.
    View in: PubMed
    Score: 0.031
  67. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
    View in: PubMed
    Score: 0.031
  68. Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. Circ Cardiovasc Interv. 2016 May; 9(5):e003114.
    View in: PubMed
    Score: 0.029
  69. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
    View in: PubMed
    Score: 0.029
  70. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. J Am Coll Cardiol. 2016 Feb 09; 67(5):596-8.
    View in: PubMed
    Score: 0.029
  71. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016 Jan 05; 67(1):81-99.
    View in: PubMed
    Score: 0.028
  72. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014 Nov 19; 312(19):2019-27.
    View in: PubMed
    Score: 0.026
  73. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA?CER) trial. Eur Heart J. 2013 Jun; 34(23):1723-31.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.